18464360. C-RAF Mutants that Confer Resistance to RAF Inhibitors simplified abstract (DANA-FARBER CANCER INSTITUTE, INC.)
Contents
- 1 C-RAF Mutants that Confer Resistance to RAF Inhibitors
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 C-RAF Mutants that Confer Resistance to RAF Inhibitors - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
C-RAF Mutants that Confer Resistance to RAF Inhibitors
Organization Name
DANA-FARBER CANCER INSTITUTE, INC.
Inventor(s)
Caroline Emery of Kansas City MO (US)
Rajee Antony of Norwood MA (US)
Levi A. Garraway of Newton MA (US)
C-RAF Mutants that Confer Resistance to RAF Inhibitors - A simplified explanation of the abstract
This abstract first appeared for US patent application 18464360 titled 'C-RAF Mutants that Confer Resistance to RAF Inhibitors
Simplified Explanation
The patent application describes nucleic acids and proteins with a mutant C-RAF sequence for identifying cancer patients who may benefit from combination therapy.
- Mutant C-RAF sequence in nucleic acids and proteins
- Methods for identifying cancer patients suitable for combination therapy
- Methods for treatment
Potential Applications
The technology can be applied in:
- Personalized medicine
- Cancer treatment
Problems Solved
The technology helps in:
- Identifying patients who will benefit from combination therapy
- Tailoring treatment to individual patients
Benefits
The benefits of this technology include:
- Improved treatment outcomes
- Reduced side effects from unnecessary therapies
Potential Commercial Applications
The technology can be commercially applied in:
- Pharmaceutical companies
- Biotechnology firms
Possible Prior Art
Prior art may include:
- Previous patents on cancer treatment methods
- Research articles on C-RAF mutations in cancer
Unanswered Questions
How does the mutant C-RAF sequence impact cancer treatment outcomes?
The patent application does not delve into the specific mechanisms by which the mutant C-RAF sequence affects treatment outcomes.
Are there any potential side effects associated with using this technology?
The patent application does not address any potential side effects that may arise from utilizing this technology.
Original Abstract Submitted
Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.
